Category Archives: Psoriasis

New York, March 30, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Anti-Inflammatory Therapeutics Industry" - https://www.reportlinker.com/p06039956/?utm_source=GNW In addition to being a global intelligence exchange platform, MarketGlass is a powerful knowledge center that delivers dynamic project-focused market intelligence. Client companies will have complete insider access to the project Data stack. - Interactive peer-to-peer and enterprise-to-enterprise ideation and market intelligence exchange is facilitated via a robust, secure, and validated process. The process draws from uniquely qualified project-specific and geographically focused executives overseeing business development, marketing and sales operations.

Abstract: - Global Anti-Inflammatory Therapeutics Market to Reach $135.5 Billion by 2027 - Amid the COVID-19 crisis, the global market for Anti-Inflammatory Therapeutics estimated at US$97.8 Billion in the year 2020, is projected to reach a revised size of US$135.5 Billion by 2027, growing at a CAGR of 4.8% over the analysis period 2020-2027. Anti-Inflammatory Biologics, one of the segments analyzed in the report, is projected to record a 5.2% CAGR and reach US$67.4 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) segment is readjusted to a revised 4.5% CAGR for the next 7-year period. - The U.S. Market is Estimated at $26.5 Billion, While China is Forecast to Grow at 7.3% CAGR - The Anti-Inflammatory Therapeutics market in the U.S. is estimated at US$26.5 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$27.7 Billion by the year 2027 trailing a CAGR of 7.4% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.6% and 4.3% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 2.9% CAGR. - Corticosteroids Segment to Record 4.2% CAGR - In the global Corticosteroids segment, USA, Canada, Japan, China and Europe will drive the 3.8% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$12.4 Billion in the year 2020 will reach a projected size of US$16.1 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$18 Billion by the year 2027, while Latin America will expand at a 5.2% CAGR through the analysis period.

- Select Competitors (Total 42 Featured) -

Read the full report: https://www.reportlinker.com/p06039956/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW Influencer Market Insights World Market Trajectories Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE Table 1: World Current & Future Analysis for Anti-Inflammatory Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR

Table 2: World Historic Review for Anti-Inflammatory Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 3: World 15-Year Perspective for Anti-Inflammatory Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2020 & 2027

Table 4: World Current & Future Analysis for Anti-Inflammatory Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR

Table 5: World Historic Review for Anti-Inflammatory Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 6: World 15-Year Perspective for Anti-Inflammatory Biologics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

Table 7: World Current & Future Analysis for Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR

Table 8: World Historic Review for Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 9: World 15-Year Perspective for Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

Table 10: World Current & Future Analysis for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR

Table 11: World Historic Review for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 12: World 15-Year Perspective for Corticosteroids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

Table 13: World Current & Future Analysis for Arthritis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR

Table 14: World Historic Review for Arthritis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 15: World 15-Year Perspective for Arthritis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

Table 16: World Current & Future Analysis for Respiratory Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR

Table 17: World Historic Review for Respiratory Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 18: World 15-Year Perspective for Respiratory Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

Table 19: World Current & Future Analysis for Multiple Sclerosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR

Table 20: World Historic Review for Multiple Sclerosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 21: World 15-Year Perspective for Multiple Sclerosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

Table 22: World Current & Future Analysis for Psoriasis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR

Table 23: World Historic Review for Psoriasis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 24: World 15-Year Perspective for Psoriasis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

Table 25: World Current & Future Analysis for Inflammatory Bowel Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR

Table 26: World Historic Review for Inflammatory Bowel Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 27: World 15-Year Perspective for Inflammatory Bowel Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

Table 28: World Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR

Table 29: World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 30: World 15-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

UNITED STATES Table 31: USA Current & Future Analysis for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 32: USA Historic Review for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 33: USA 15-Year Perspective for Anti-Inflammatory Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids for the Years 2012, 2020 & 2027

Table 34: USA Current & Future Analysis for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 35: USA Historic Review for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 36: USA 15-Year Perspective for Anti-Inflammatory Therapeutics by Indication - Percentage Breakdown of Value Sales for Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Indications for the Years 2012, 2020 & 2027

CANADA Table 37: Canada Current & Future Analysis for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 38: Canada Historic Review for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 39: Canada 15-Year Perspective for Anti-Inflammatory Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids for the Years 2012, 2020 & 2027

Table 40: Canada Current & Future Analysis for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 41: Canada Historic Review for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 42: Canada 15-Year Perspective for Anti-Inflammatory Therapeutics by Indication - Percentage Breakdown of Value Sales for Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Indications for the Years 2012, 2020 & 2027

JAPAN Table 43: Japan Current & Future Analysis for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 44: Japan Historic Review for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 45: Japan 15-Year Perspective for Anti-Inflammatory Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids for the Years 2012, 2020 & 2027

Table 46: Japan Current & Future Analysis for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 47: Japan Historic Review for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 48: Japan 15-Year Perspective for Anti-Inflammatory Therapeutics by Indication - Percentage Breakdown of Value Sales for Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Indications for the Years 2012, 2020 & 2027

CHINA Table 49: China Current & Future Analysis for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 50: China Historic Review for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 51: China 15-Year Perspective for Anti-Inflammatory Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids for the Years 2012, 2020 & 2027

Table 52: China Current & Future Analysis for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 53: China Historic Review for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 54: China 15-Year Perspective for Anti-Inflammatory Therapeutics by Indication - Percentage Breakdown of Value Sales for Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Indications for the Years 2012, 2020 & 2027

EUROPE Table 55: Europe Current & Future Analysis for Anti-Inflammatory Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR

Table 56: Europe Historic Review for Anti-Inflammatory Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 57: Europe 15-Year Perspective for Anti-Inflammatory Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2020 & 2027

Table 58: Europe Current & Future Analysis for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 59: Europe Historic Review for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 60: Europe 15-Year Perspective for Anti-Inflammatory Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids for the Years 2012, 2020 & 2027

Table 61: Europe Current & Future Analysis for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 62: Europe Historic Review for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 63: Europe 15-Year Perspective for Anti-Inflammatory Therapeutics by Indication - Percentage Breakdown of Value Sales for Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Indications for the Years 2012, 2020 & 2027

FRANCE Table 64: France Current & Future Analysis for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 65: France Historic Review for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 66: France 15-Year Perspective for Anti-Inflammatory Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids for the Years 2012, 2020 & 2027

Table 67: France Current & Future Analysis for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 68: France Historic Review for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 69: France 15-Year Perspective for Anti-Inflammatory Therapeutics by Indication - Percentage Breakdown of Value Sales for Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Indications for the Years 2012, 2020 & 2027

GERMANY Table 70: Germany Current & Future Analysis for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 71: Germany Historic Review for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 72: Germany 15-Year Perspective for Anti-Inflammatory Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids for the Years 2012, 2020 & 2027

Table 73: Germany Current & Future Analysis for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 74: Germany Historic Review for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 75: Germany 15-Year Perspective for Anti-Inflammatory Therapeutics by Indication - Percentage Breakdown of Value Sales for Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Indications for the Years 2012, 2020 & 2027

ITALY Table 76: Italy Current & Future Analysis for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 77: Italy Historic Review for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 78: Italy 15-Year Perspective for Anti-Inflammatory Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids for the Years 2012, 2020 & 2027

Table 79: Italy Current & Future Analysis for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 80: Italy Historic Review for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 81: Italy 15-Year Perspective for Anti-Inflammatory Therapeutics by Indication - Percentage Breakdown of Value Sales for Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Indications for the Years 2012, 2020 & 2027

UNITED KINGDOM Table 82: UK Current & Future Analysis for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 83: UK Historic Review for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 84: UK 15-Year Perspective for Anti-Inflammatory Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids for the Years 2012, 2020 & 2027

Table 85: UK Current & Future Analysis for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 86: UK Historic Review for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 87: UK 15-Year Perspective for Anti-Inflammatory Therapeutics by Indication - Percentage Breakdown of Value Sales for Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Indications for the Years 2012, 2020 & 2027

SPAIN Table 88: Spain Current & Future Analysis for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 89: Spain Historic Review for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 90: Spain 15-Year Perspective for Anti-Inflammatory Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids for the Years 2012, 2020 & 2027

The rest is here:
Global Application Container Market to Reach $9.7 Billion by 2027 - Benzinga

Yes.

In a variety of studies, testosterone was found to be significantly decreased in people with psoriasis.

In men, lower levels of testosterone are associated with:

As you might expect, studies also revealed that total sperm count, sperm motility and percent of sperm with normal morphology were significantly reduced in participants with psoriasis.

Fewer available sperm and sperm motility issues can make it harder to conceive spontaneously.

These findings suggest that untreated psoriasis may impair male fertility.

The link between psoriasis and decreased fertility may be due to how systemic inflammation affects the production of sex hormones.

Inflammation triggers a cascade of inflammatory cytokines (a type of protein), which can have a destructive impact on a variety of organ systems, including reproductive systems. This influx of cytokines may lead to decreasing sex hormone production and sperm production.

The link may also be related to the inflammation of sexual accessory glands. In one small 2017 study, 70 percent of participants with psoriasis were found to have ultrasound signs of inflammation of the accessory glands. No one in the non-psoriasis control group showed these signs.

Sexual accessory glands in men include the seminal vesicles and prostate. These glands help to create the fluids in semen that protect and transport sperm. Inflammation in these glands could also negatively affect sperm, decreasing chances of conception.

Psoriasis treatments aimed at decreasing systemic inflammation, such as anti-TNF agents, have been shown to improve male fertility.

Anti-TNF medications currently approved by the Food and Drug Administration (FDA) for treating psoriasis include:

However, some other immunosuppressant medications, like sulfasalazine, show evidence of decreasing sperm quality. That said, there currently isnt enough evidence to definitively determine which are beneficial or harmful to sperm production and fertility.

Any autoimmune disease or condition that leads to significant systemic inflammation can affect fertility.

This includes conditions like:

Yes, by seeking early treatment to prevent and control any systemic inflammation.

The first step is working with your doctor on a treatment that manages the disease well enough to avoid systemic inflammation. Your treatment is likely to include medications and lifestyle modification to help avoid flares.

These lifestyle modifications may include things like:

Dr. Susan Bard is a NYC-based board certified dermatologist and fellow of the American College of Mohs Surgery. Dr. Bard received her medical degree from SUNY Downstate. She completed her dermatology residency at the University of Miami as well as a clinical research fellowship in pediatric dermatology and a procedural dermatology fellowship, where she further trained in Mohs micrographic surgery, lasers, and cosmetic surgery.

More:
Ask the Expert: The Link Between Psoriasis and Male Fertility - Healthline

Psoriasis is a chronic, noncontagious skin condition that causes skin cells to build up and form red, inflamed patches.

Following decades of research, doctors remain unclear as to the exact causes of psoriasis. But they understand that the immune system, genetics, and environmental factors can play a key role.

This article will look at psoriasis and the immune system and how to boost immunity. It will then explore possible complications of psoriasis, as well as triggers and treatments.

Many experts classify psoriasis as an autoimmune disorder, although others disagree. One alternative theory is that psoriasis occurs because the immune system reacts irregularly to bacteria on the skin due to genetics.

In an autoimmune disease, specific triggers cause the immune system to malfunction. These triggers vary between individuals. But in the case of psoriasis, they can include stress and skin trauma, such as insect bites, sunburn, and scratches.

In psoriasis, the activated immune system mistakenly launches an inflammatory response. It begins to attack healthy cells as though they were harmful invading pathogens. White blood cells called T helper lymphocytes, or T cells, become irregularly active and produce excess signaling molecules.

These cytokine molecules cause the blood vessels in the skin to widen. In turn, this causes white blood cells to accumulate, and keratinocytes, which make up the outer layer of the skin, to multiply much faster than usual.

In psoriasis, the process of a cell dividing, maturing, migrating to the skins surface, and sloughing off is complete in as few as 37 days, compared with 34 weeks in a person without psoriasis.

The result of this skin buildup is thickened, flushed, and scaly skin plaques.

Learn what psoriasis on black skin can look like here.

Learn five facts about psoriasis and the immune system here.

There are many different types of psoriasis.

Researchers believe that a combination of factors can cause an individual to develop psoriasis.

In some cases, genetics can be a cause, as the condition often runs in families. If a child has one affected parent, they have a 16% chance of developing psoriasis. With both parents, the chance jumps to 50%.

But some individuals with no family history may also develop psoriasis. This finding highlights the effect environmental factors such as stress, smoking, and diet may have on psoriasis development.

Having a properly functioning immune system is essential to health.

There are various ways that individuals with psoriasis can regulate their immune systems through diet and exercise.

According to a 2018 study, following a Mediterranean diet can slow the progression of psoriasis since it reduces inflammation.

The Mediterranean diet consists of the following:

People use this yellow spice in cooking and natural medicines. Turmeric may positively impact someones immune response.

According to one 2017 paper, the curcumin found in turmeric has antioxidant and anti-inflammatory effects.

So, turmeric may reduce symptoms of many conditions that inflammation can worsen, including psoriasis.

Garlic may boost the immune system.

One 2014 review showed that study participants taking a placebo had over twice as many colds between them as the people taking garlic supplements.

The researchers recommended further research to confirm the immune-modulating effects of garlic.

Regular exercise can improve immune system functions.

One study found that 3060 minutes of daily brisk walking improves the bodys defense system.

Regular exercise can also be important for people with psoriasis, as it can reduce the risk of other complications they are more likely to experience, such as high blood pressure or diabetes.

Psoriasis appears on the skin and nails, but problems with the immune system that cause psoriasis can cause other conditions alongside it.

Psoriatic arthritis, or joint inflammation, occurs in around 30% of people with psoriasis.

Psoriatic arthritis can be a painful and destructive inflammatory type of arthritis. But symptoms may reduce with treatment.

Psoriasis can mean a person has a higher risk of developing cardiovascular diseases such as:

This is possibly due to the inflammation that occurs with all the conditions.

People with psoriasis may feel emotional distress that disrupts their regular social interactions or working life.

According to a 2018 study, people with psoriasis have an increased risk of experiencing depression and anxiety.

Individuals with psoriasis may have different triggers, and the condition may run in families.

Common triggers that can cause flare-ups in people with psoriasis can include:

Learn about the causes of psoriasis here.

If psoriasis is mild, treatment with a skin moisturizer, medicated shampoo, and exposure to sunlight may be enough to alleviate symptoms.

But most people require medical therapies to manage their psoriasis. Options include:

Corticosteroid ointments, gels, and lotions of varying strengths can reduce inflammation and itching.

Long-term use of potent topical corticosteroids can cause skin thinning and damage. So, doctors may recommend forms of vitamin D and vitamin A instead of, or in conjunction with, steroid use. They may also prescribe corticosteroid-free, immune-modulating topicals for delicate areas instead.

Doctors can use UV radiation to treat moderate to severe psoriasis.

They may prescribe UVB in combination with other topical medications and reserve UVA for psoriasis that does not respond to other treatments.

Learn about light therapy for psoriasis here.

Learn about home remedies to ease psoriasis here.

Doctors remain unclear as to the exact causes of psoriasis. There is evidence for genetic involvement, as those with a family history of psoriasis are more likely to have it themselves.

Psoriasis appears to be an autoimmune response, with specific triggers causing the immune system to react against healthy tissue.

Although it cannot be cured, individuals can manage the symptoms with various therapies. These include topical corticosteroid creams, phototherapy, and biologic immunosuppressant agents.

Further research is needed to understand the inheritance and immune system involvement of psoriasis.

View original post here:
Psoriasis and the immune system: Relationship, causes, and more - Medical News Today

Psoriatic arthritis (PsA) is an inflammatory form of arthritis that causes swollen, stiff, and painful joints.

PsA affects about 30 percent of people with psoriasis, a skin condition characterized by scaly, red skin patches.

Hypothyroidism affects your thyroid the butterfly-shaped gland in your neck that produces hormones. When you have hypothyroidism, this gland doesnt make enough thyroid hormones.

The most common cause of hypothyroidism is Hashimotos thyroiditis, an autoimmune condition in which white blood cells of the immune system mistakenly attack cells in the thyroid gland.

PsA and psoriasis are also autoimmune disorders. These conditions cause your immune system to attack healthy joints and skin. In hypothyroidism, your immune systems target is the thyroid gland.

Read on to learn how these two conditions are related.

Psoriasis isnt a symptom of hypothyroidism. But if you have psoriasis or PsA, youre more likely to have at least one other autoimmune disease, including:

In autoimmune thyroid disease, the immune system makes proteins called antibodies that damage the thyroid gland.

People with PsA and psoriasis are more likely to test positive for thyroid antibodies than people without these conditions. In one study, about a third of people with psoriasis had a thyroid condition, too.

Thyroid hormones act on many different parts of your body, including your skin. These hormones may trigger psoriasis and make symptoms worse.

Thyroid hormones increase the level of growth factors that cause the skin cells that form scaly psoriasis plaques to multiply. Excess thyroid hormone production makes psoriasis worse.

Hypothyroidism isnt a skin disease. But like psoriasis and PsA, it can affect your skin.

Skin symptoms of hypothyroidism include:

A few different triggers can result in flares of psoriasis or make the skin condition worse. Common psoriasis triggers include:

Some medications also cause psoriasis flare-ups. Certain prescription drugs can:

The medications most likely to cause a psoriasis flare-up are:

It usually takes 2 to 3 weeks after you start taking a new drug for psoriasis symptoms to appear. If you stop taking a corticosteroid drug such as prednisone too quickly, it can also set off a psoriasis flare.

If you take one of these medications and notice that your psoriasis is getting worse, dont stop taking it. Talk with your doctor instead. Ask if you can switch to another drug that wont affect your skin.

Generalized myxedema is a complication of severe hypothyroidism. It causes:

Doctors treat myxedema rash with corticosteroid creams and injections.

Pretibial myxedema (PTM) is a red, swollen, and thick skin rash. Its a rare symptom of thyroid conditions such as Hashimotos thyroiditis and Graves disease.

This rash forms when hyaluronic acid, a natural lubricant your body makes, builds up under your skin. The affected skin becomes thick and has the texture of an orange peel.

PTM most often appears on the shins or the tops of the feet. It also can form on areas like your:

Reach out to a doctor if you have symptoms of PsA or Hashimotos thyroiditis that dont go away.

PsA symptoms include:

Hashimotos thyroiditis symptoms include:

Your doctor will ask about your symptoms and medical history. You may need blood tests to find out whether your thyroid hormone level is too low or imaging tests to check your joints for damage.

PsA and hypothyroidism are both types of autoimmune disorders. When you have PsA or psoriasis, youre also more likely to have thyroid disease.

If you have symptoms of PsA or hypothyroidism, contact your doctor for an exam. Treatments can slow the joint damage and skin plaques of PsA as well as restore normal hormone levels in hypothyroidism.

See more here:
Psoriatic Arthritis and Hypothyroidism: Are They Related? - Healthline

When Johnson & Johnson scored approval for Tremfya inpsoriatic arthritis last year, the company set outin crowded field withentrenched competition. But now thedrugmakerhasnew long-term datato bolsterits drugs case.

Indata from an extended phase 3 trial,more than half of adults on Tremfya achieved complete skin clearance at two years,J&J said. More than 70% of patients achieved 20% improvement or betterin joint symptoms.Previously, the drug showed benefits through 24 weeksleadingto an FDA approval last yearand through 52 weeks.

Specifically, among patients who had experienced clinically meaningful skin involvement at baseline, 59% of patients who received Tremfya every four weeksand 53% of those who received the drug every eight weeksexperienced complete skin clearance, J&J said.

About 90% of patients randomized toreceiveTremfya in the study continued their treatment through100 weeks, J&J said.Aside from the skin clearance and joint symptom effects, the two-year data confirmed earlierfindingsdemonstrating the meds benefits tophysical function and other quality-of-life factors, J&J said.

The results further bolster our confidence in the ability of Tremfya to significantly improve the diverse manifestations ofPsAover time, Janssen R&D rheumatology disease area leader Alyssa Johnson said in a statement.

RELATED:J&J's Tremfya grabs psoriatic arthritis nod, setting up a battle with Cosentyx, Taltz and more

Investigators are presenting the data at theInnovations in Dermatology virtual spring meeting.

The resultsgive J&Ja stepped-up talking point in a competitivefield. When Tremfya won itsFDA approval in psoriatic arthritis last year, the company set out to launch its drug against meds from AbbVie, Novartis and Eli Lilly. Plus, Lillys Taltz boastshead-to-head dataover the J&J drug.

RELATED:Johnson & Johnson's Tremfya backs psoriatic arthritis play with newest data

J&Js Tremfya, first approved inlate 2017 to treat plaque psoriasis,generated$1.35 billion last year.

Follow this link:
Challenging AbbVie and Lilly in psoriatic arthritis, J&J touts 2-year data for Tremfya - FiercePharma

Michael Vi/Shutterstock

Long-term data from Janssens Phase III DISCOVER-2a trial show that TREMFYA (guselkumab), a selective IL-23 inhibitor, lead to skin clearance and joint symptom relief for up to two years in patients with active psoriatic arthritis (PsA).

Janssens TREMFYA was approved for the treatment of adults with moderate to severe plaque psoriasis (PsO) in the U.S. back in July 2017 and then again in July 2020 for adults with active PsA. The latter approval was based on trial data from the DISCOVER-1 and DISCOVER-2, both of which showed that the treatment led to at least 20% improvement in joint symptoms (ACR 20) by 24 weeks.

TREMFYA is a selective inhibitor of IL-23, a key cytokine that fuels an inflammatory immune response associated with symptoms of PsO and PsA.

"PsA can be a chronically painful and debilitating disease, and many PsA patients are still searching for enduring relief of their symptoms," said study investigator Philip J. Mease, M.D., of the Swedish Medical Center/Providence St. Joseph Health and the University of Washington, Seattle, Washington. "These data, which show that the observed benefits of TREMFYA in PsA continue through two years, represent positive news for physicians and patients alike."

Findings from the new trial show that 56% and 55% of patients who took TREMFYA every four and every eight weeks, respectively, experienced at least a 50% improvement in the ACR score through 100 weeks. Approximately 62% of patients who took TREMFYA every 4 weeks and 55% of patients who took TREMFYA every eight weeks with clinically meaningfulbaseline PsO also achieved complete skin clearance by follow up.

Approximately 59% and 53% of those who had clinically meaningful baseline skin involvement who received TREMFYA every four weeks and eight weeks, respectively, experienced complete skin clearance by week 100. Additionally, 76% of patients treated with TREMFYA every four weeks and 74% treated every eight weeks had at least a 20% improvement in the ACR by the long-term follow-up period.

TREMFYA every four weeks also demonstrated significant inhibition of radiographic progression of joint structural damage at week 24. Rates of radiographic progression of joint damage observed from week 52 to 100 in patients who received the treatment every four and eight weeks were also numerically lower than those reported from baseline to week 52.

In terms of durability, the investigators of the DISCOVER-2a trial found that treatment with TREMFYA led to robust joint and skin response rates and improvements in outcome measures through the two-year follow-up period. Up to 90% of patients randomly assigned to TREMFYA also continued their assigned therapy through week 100. Overall, no new safety signals were observed through week 112.

"PsA is a chronic inflammatory disease of the skin, joints, and soft tissue and therefore, sustained control of this inflammation is important to physicians and patients," saidAlyssa Johnsen, M.D., Ph.D., Janssen Research & Developments Vice President and Rheumatology Disease Area Leader. "These long-term study results further bolster our confidence in the ability of TREMFYA to significantly improve the diverse manifestations of PsA over time."

Janssen said in a statement that the data from the DISCOVER-2a trial will soon be presented in abstract, poster, and video form during the Innovations in Dermatology: Virtual Spring Conference, held March 16 through 20, 2021.

Most Read Today

Go here to see the original:
Janssen's Psoriatic Arthritis Drug Proves Long-Term Efficacy in Two-Year Trial - BioSpace

This article was originally published here

J Rheumatol. 2021 Mar 15:jrheum.201671. doi: 10.3899/jrheum.201671. Online ahead of print.

ABSTRACT

The coronavirus disease 2019 (COVID-19; caused by SARS-CoV-2) pandemic has affected the healthcare system on a global scale, and we utilized the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2020 annual meeting to examine how COVID-19 might affect patients with psoriatic disease (PsD) and the clinicians who care for them. Pressing issues and concerns identified included whether having psoriasis increased the risk of acquiring COVID-19, vaccine safety, and the acceptability of telehealth. The general message from rheumatologists, dermatologists, infectious disease specialists, and patient research partners was that data did not suggest that having PsD or its treatment significantly increased risk of infection or more severe disease course, and that the telehealth experience was a success overall.

PMID:33722951 | DOI:10.3899/jrheum.201671

Read the original:
Psoriasis and Psoriatic Arthritis in the Context of the COVID-19 Pandemic: A Plenary Session From the GRAPPA 2020 Annual Meeting - DocWire News

WESTLAKE VILLAGE, Calif., March 17, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, will present safety, efficacy, and patient-reported outcomes from its Phase 2 open-label long-term safety study investigating roflumilast 0.3% cream in adult patients with mild-to-severe chronic plaque psoriasis at the Innovations in Dermatology: Virtual Spring Conference 2021.

Psoriasis can significantly impact all aspects of a patients life, including adverse physical, emotional, and social effects, said Dr. Linda Stein Gold, MD, Henry Ford Health System and Chair, Innovations in Dermatology. Current topical treatments for plaque psoriasis are often ineffective for long-term treatment, are not well tolerated, or are ill-suited for use in some areas of the body. We are excited to present data demonstrating that roflumilast addresses these limitations with the added benefit of a favorable long-term safety and efficacy profile.

A poster presentation will feature new long-term efficacy and safety data on topical roflumilast 0.3% cream at 52- to 64-weeks (Dr. Linda Stein Gold). Additionally, two poster presentations will feature analyses of improved burden of signs and symptoms and improved itch severity (Dr. Leon Kircik), and itch-related sleep loss in adults with chronic plaque psoriasis (Dr. Linda Stein Gold) from the original Phase 2b study of roflumilast cream over a 12-week treatment period.

Arcutis also recently released positive topline data from the pivotal Phase 3 studies of roflumilast cream in plaque psoriasis, and plans to present the full results of those studies in the near future, as well as submit a New Drug Application later this year.

In addition to the plaque psoriasis presentations, Dr. Melinda Gooderham will present the results from the Phase 2 study of roflumilast cream 0.15% and 0.05% in patients with mild-to-moderate atopic dermatitis.

Existing topical treatments prescribed to psoriasis patients have significant shortcomings, which lead to difficult trade-offs between efficacy, safety, and tolerability, said Patrick Burnett, M.D., Ph.D., FAAD, Arcutis Chief Medical Officer. These data reinforce our conviction that topical roflumilast, if approved by the FDA, has the potential to revolutionize the standard of care in plaque psoriasis and other inflammatory dermatological conditions by reducing the need to make such trade-offs.

Arcutis is investigating roflumilast as a once-daily, nonsteroidal treatment for plaque psoriasis, atopic dermatitis, seborrheic dermatitis, and scalp psoriasis. Roflumilast cream is a once daily topical formulation of roflumilast, a highly potent and selective phosphodiesterase type 4 inhibitor (PDE4). Based on results from the pivotal Phase 3 studies, topical roflumilast potentially delivers efficacy comparable to the results of published clinical studies of high-potency steroid/calcipotriene or high-potency steroid/tazarotene combination products, but with safety and tolerability that supports chronic use in all areas of the body, and little or none of the local tolerability issues associated with many competitive agents.

For more information, visit the Innovations in Dermatology Spring Conference virtually and https://www.arcutis.com or follow the company on LinkedIn and Twitter.

About Plaque PsoriasisPsoriasis is a common, non-contagious, immune-mediated skin disease that affects approximately 8.6 million patients in the United States. About 90% of patients develop plaque psoriasis, which is characterized by raised, red areas of skin covered with a silver or white layer of scale. Psoriatic plaques can appear on any area of the body, but most often appear on the scalp, knees, elbows, trunk, and limbs, and are often itchy and sometimes painful. Plaques in certain anatomical areas present particular treatment challenges, including the face, elbows and knees, scalp, and intertriginous regions such as the groin, axillae and inframammary areas.

About Atopic DermatitisAtopic dermatitis (AD) is the most common type of eczema, occurring in approximately 6% of the U.S. population. AD is characterized by a defect in the skin barrier, which allows allergens and other irritants to enter the skin, leading to an immune reaction and inflammation. This reaction produces a red, itchy rash, most frequently occurring on the face, arms and legs, and the rash can cover significant areas of the body, in some cases half of the body or more. Disease onset is most common by 5 years of age, and the Company estimates that approximately 60% of patients suffering from AD are pediatric patients. The rash causes significant pruritus (itching), which can lead to skin damage caused by scratching or rubbing. Given that most of the patients are pediatric, the safety and tolerability of AD therapies is paramount.

About Topical Roflumilast CreamRoflumilast Cream is a topical cream formulation of a highly potent and selective PDE4 inhibitor (roflumilast). Roflumilast has been approved by the U.S. Food and Drug Administration (FDA) for oral treatment to reduce the risk of exacerbations of chronic obstructive pulmonary disease (COPD) since 2011. Roflumilast has shown greater potency (25- to 300-fold) than the two other FDA-approved PDE4 inhibitors for dermatology. PDE4 is an intracellular enzyme that increases the production of pro-inflammatory mediators and decreases production of anti-inflammatory mediators and has been implicated in a wide range of inflammatory diseases including psoriasis, eczema, and COPD. PDE4 is an established target in dermatology, and other PDE4 inhibitors have been approved by the FDA for the topical treatment of atopic dermatitis and the systemic treatment of plaque psoriasis.

About ArcutisArcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology. The company is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. Arcutis robust pipeline includes four novel drug candidates currently in development for a range of inflammatory dermatological conditions. The companys lead product candidate, topical roflumilast, has the potential to revitalize the standard of care for plaque psoriasis, atopic dermatitis, scalp psoriasis, and seborrheic dermatitis. For more information, visit https://www.arcutis.com or follow the company on LinkedIn and Twitter.

Forward Looking StatementsThis press release contains "forward-looking" statements, including, among others, statements regarding the potential for roflumilast to revolutionize the standard of care in plaque psoriasis and other inflammatory dermatological conditions. These statements involve substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements and you should not place undue reliance on our forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in the clinical development process and regulatory approval process, the timing of regulatory filings, and our ability to defend our intellectual property. For a further description of the risks and uncertainties applicable to our business, see the "Risk Factors" section of our Form 10-K filed with U.S. Securities and Exchange Commission (SEC) on February 16, 2021, as well as any subsequent filings with the SEC. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.

Investor and Media ContactHeather Rowe Armstrongharmstrong@arcutis.com 805-418-5006 ext. 740

Read more here:
Arcutis Biotherapeutics to Showcase Long-term Safety, Efficacy, and Patient-Reported Outcomes of Roflumilast Cream for Chronic Plaque Psoriasis at...

You may not have a choice about needing a mobility aid, but how you feel about it is completely up to you.

If someone had told me at 25 that I would be walking with a cane by age 30, I wouldnt have believed them.

In my case, the cause wasnt injury or accident, but psoriatic arthritis (PsA) a chronic, autoimmune disease that causes inflammation, joint pain, fatigue, and mobility limitations in 30 percent of people with psoriasis.

During the first arthritis flare-up that landed me in the hospital, I literally could not stand on my own feet.

Over the next several years, as doctors prescribed one medication regimen after another, I faced a daunting new reality: I could no longer walk without assistance.

How could I find the right mobility device to suit my needs and how could I get used to moving through the world with it?

Here are a few things I learned in my search to restore my mobility and maximize my quality of life with PsA.

Several weeks after the onset of PsA, I found I was still unable to walk, so I bought the cheapest manual wheelchair I could find. I chose a wheelchair partly because it was a familiar cultural icon, and I didnt know much about my other options.

Once I delved more deeply into the world of mobility devices, I realized just how many options there are.

Broadly speaking, people with mobility issues have a choice between walking aids and seated mobility devices.

Walking aids include:

Seated mobility devices include:

Since physical activity has been shown to improve both PsA symptoms and overall health, most users will want to choose the device that allows them to be as active as possible while also staving off pain and fatigue.

My manual wheelchair served me well in the short term, before I was able to find the right combination of medications to manage my symptoms. However, I soon realized that I wanted to be more active even if it meant dealing with more physical pain.

Over the course of the next several years, as biologic drugs began to suppress some of my disease activity, I transitioned to using a rollator, then forearm crutches, and then finally, a cane.

All this experimentation was expensive. I wish I had known that many device companies allow prospective users to rent or try out different mobility aids and determine which one best suits their needs.

I also wish I had consulted with a doctor, occupational therapist, or physical therapist to learn how to use these devices correctly, since improper usage cannot only decrease the helpfulness of your mobility aid, but may even have a negative impact on your posture or cause you greater discomfort.

When choosing your own mobility device(s), be open to multiple possibilities and dont be shy about asking for information on device usage from those in the know.

Even when I first got diagnosed with PsA, the last thing I wanted was to feel like a sick person.

I soon realized that I could keep my life as active and vibrant as possible by taking an open-minded, strategic approach to mobility aids.

Its true that certain activities like skiing, hiking, and climbing are no longer feasible for me, but Im lucky to be mobile enough that there are many things I can still do, if I have the right mobility aid on hand.

For instance, my arm crutches are ideal for nature walks, since they stabilize and support both sides of my body while leaving me flexible to maneuver.

When going to a museum or other accessible indoor attraction, I opt for a wheelchair, which lets me move through the space smoothly and view exhibits without pain or fatigue.

Now that my symptoms are mostly well-controlled, thanks to medication, I can often get by with a folding cane. It provides minimal support when I get tired, and it also serves as a signaling device to alert people that I may move slowly or need to sit down from time to time.

When choosing the mobility aid thats right for you, think about what you want or need to get done on a particular day. Ask yourself what accessibility challenges you might encounter, and which device would help you face them with comfort and confidence.

Prior to my PsA diagnosis, I assumed that disability was a stable, fixed category or, at least, a linear progression from wellness to illness.

One of the most surprising aspects of living with a chronic disease is how much my symptoms can fluctuate from one day or week to the next. Even in a single day, I often have periods in the morning and at night when my joints feel stiff and my range of motion is limited.

Once you know to expect these fluctuations, you become better able to plan your day even if that means expecting a bit of unpredictability.

These emotional and logistical aspects of living with PsA require both flexibility and resilience.

It can be discouraging to lapse into an arthritis flare-up and find oneself back in a wheelchair after weeks of walking around with a less intensive mobility aid.

It can also be frustrating to find that certain devices may not work well for you at times when particular joints are giving you trouble. For instance, forearm crutches can be terrific for taking pressure off of weak knees or ankles, but they put a significant strain on a users shoulders and wrists.

As you pick a mobility aid, check in with yourself to figure out which body parts need extra support, and be prepared for the prospect that your mobility needs might shift depending on factors like the time of day or the weather.

The changeable nature of PsA symptoms can be hard for nondisabled onlookers to understand.

I have had friends ask me excitedly if I was cured when they saw me using a cane on a good day, instead of my usual rollator.

Conversely, Ive encountered nosiness and skepticism from colleagues who had only met me at a meeting, seated, and later ran into me on the street and demanded, Whats with the cane?

Try not to get thrown off by these moments, and try not to feel like youre pretending or being dramatic by making use of a mobility aid. Only you are inside your body only you know what you need.

For me, the adjustment to this new world of mobility aids was emotionally fraught, since it meant reconciling myself to the fact of my disability. After all, those of us with PsA dont use our mobility aids in the way someone with a broken leg might use crutches.

We know that our symptoms are treatable with medication, but that PsA cant be cured. As a result, we may feel the need to integrate mobility devices into our sense of identity.

This can be difficult, especially if one doesnt use the same device every day. No matter what, it takes time to get used to how it feels to use a mobility aid.

Accepting that these tools are extensions of your body tools that accompany you through the world and help you live the life you want takes even longer.

Be patient with others, and with yourself, as you figure out which equipment works best for you.

You may not have a choice about how large a role mobility aids play in your daily routine, but how you feel about them is completely up to you.

Michael M. Weinstein has written about disability, illness, and gender for venues including The New Yorker, The Los Angeles Review of Books, and Michigan Quarterly Review. He holds a PhD in English from Harvard and an MFA from the University of Michigan, where hes currently a Zell Creative Writing Fellow. Hes currently at work on a book about the social and romantic lives of transgender Americans. You can find him on Twitter and Instagram.

Go here to read the rest:
4 Tips for Navigating the World of Mobility Aids for PsA - Healthline

The joint and skin response rates of adults with active psoriatic arthritis observed with Tremfya (guselkumab) were maintained over two years.

The Janssen Pharmaceutical Companies of Johnson & Johnson have released long-term data from the Phase III DISCOVER-2 study showing that the skin clearance, joint symptom relief and safety of Tremfya(guselkumab) previously demonstrated through 24 weeks and one year (week 52) in adults with active psoriatic arthritis (PsA) continued through two years (week 112).

Tremfya is currently the only IL-23 inhibitor therapy approved in the US to treat both adults with active PsA and adults with moderate to severe plaque psoriasis (PsO). The PsA approval was based on results from DISCOVER-1 and DISCOVER-2 previously published inThe Lancet.

At week 100, 59 percent of patients receiving Tremfya every four weeks (q4w) and 53 percent of those receiving Tremfya every eight weeks (q8w) achieved complete skin clearance (assessed using the Psoriasis Area Severity Index [PASI]). Among patients who had clinically meaningful PsO at baseline, 62 percent of Tremfya q4w patients and 55 percent of Tremfya q8w patients achieved complete skin clearance as measured by the Investigator Global Assessment (IGA) score of 0.

Additionally, 76 percent of the patients receiving Tremfya q4w and 74 percent of those receiving Tremfya q8w achieved at least 20 percent improvement in joint pain (assessed using the American College of Rheumatology [ACR 20] response criteria). Moreover, 56 percent of Tremfya q4w patients and 55 percent of Tremfya q8w patients achieved at least 50 percent improvement in ACR score.

The study also assessed radiographic progression. At 24 weeks, Tremfya q4w demonstrated statistically significant inhibition of radiographic progression of joint structural damage (measured by PsA-modified van der Heijde-Sharp [vdH-S scores]). Tremfya q8w afforded numerically, but not statistically significant, less radiographic progression compared with placebo. From week 52-100, low rates of radiographic progression of joint damage were observed in patients receiving TREMFYA q4w (0.75) and Tremfya q8w (0.46), which were both further numerically reduced from the results observed during weeks 0-52 (1.06, q4w; 0.99, q8w).

In the group of patients who crossed over from placebo to Tremfya q4w at week 24, mean changes in vdH-S scores were 1.12 from week 0-24 while receiving placebo and 0.34 from week 24-52 and 0.13 from week 52-100 while receiving Tremfya q4w, indicating that further numerical improvements were also made through year two in this group.

According to Janssen, approximately 90 percent of patients randomised to Tremfya q4w or q8w continued treatment with Tremfya through Week 100.

No new safety signals were observed in the safety analysis conducted through week 112.

PsA is a chronic inflammatory disease of the skin, joints, and soft tissue and therefore, sustained control of this inflammation is important to physicians and patients, said Dr Alyssa Johnsen, Vice President, Rheumatology Disease Area Leader, Janssen Research & Development, LLC. These long-term study results further bolster our confidence in the ability of Tremfya to significantly improve the diverse manifestations of PsA over time.

Continued here:
Data shows long-term efficacy of Tremfya in active psoriatic arthritis - European Pharmaceutical Review